Velcade Phase III Studies Will Support First-Line Use, Millennium Says
This article was originally published in The Pink Sheet Daily
The company expects to initiate three Phase III studies to support full approval of Velcade for treatment of multiple myeloma. FDA grants priority review designation to Velcade sNDA for second-line use, Millennium announces.
You may also be interested in...
The company hopes to convert Velcade's accelerated approval for third-line use to full approval and add a second-line multiple myeloma indication based on the Phase III APEX trial, which showed a significant survival benefit.
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar